Oxycontin maker Purde Pharma close to new opioids settlement
With a settlement possibly near, a judge is giving the family that owns OxyContin maker Purdue Pharma 16 more days of protection from lawsuits over opioids toll.
Source: wbir.com
Page 25 - Toby Talbot News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Toby Talbot. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Toby Talbot Today - Breaking & Trending Today
Oxycontin maker Purde Pharma close to new opioids settlement
With a settlement possibly near, a judge is giving the family that owns OxyContin maker Purdue Pharma 16 more days of protection from lawsuits over opioids toll.
Source: wthr.com
Ride On Jake
HBO’s ‘Dear Rider’ captures snowboarding’s rise and Jake Burton’s vision
Source: aspentimes.com
NICE recommends MSD's Keytruda in combination with chemotherapy for routine treatment of lung cancer
With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK. - News - PharmaTimes
Source: pharmatimes.com
![NICE Recommends MSD's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for Routine Commissioning for First-Line Treatment of Adults with Untreated Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)[1] - Vimarsana News](https://www.pharmiweb.com/media/1024/1200x448-pwjobs.png)
NICE Recommends MSD's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for Routine Commissioning for First-Line Treatment of Adults with Untreated Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)[1]
NICE Recommends MSD’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for Routine Commissioning for First-Line Treatment of Adults with Untreated Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)[1] LONDON, January 6, 2022 – Today, MSD (Merck Sharp & Dohme) (trad...
Source: pharmiweb.com